Topics:

Gastrointestinal Cancer

Gastrointestinal Cancer

Metformin, a common drug for type II diabetes, did not improve the survival of patients with pancreatic ductal adenocarcinoma.

The FDA has approved ramucirumab, a human VEGFR2 antagonist in combination with FOLFIRI for second-line treatment of patients with metastatic colorectal cancer.

In this video from the 2015 ONS meeting, Dr. Omran discusses the high-risk of colorectal cancer among the Jordanian population and the need to promote more screening awareness.

Metastatic colorectal cancer patients had about a 1.5-month increase in overall survival when treated with second-line ramucirumab plus FOLFIRI vs FOLFIRI alone.

An MRI screening program for individuals at high risk for pancreatic cancer may be effective, according to the results of a short-term study.

Patients who had either laparoscopic surgery or open surgery for localized rectal cancer had similar overall survival and disease-free survival rates.

Current use of statins was associated with about a 50% decreased risk for liver cancer, according to results of a study looking at data from the United Kingdom.

Pages

Subscribe to Gastrointestinal Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.